This was accomplished using the heavy chain and C2 domain of B domain‐deleted (BDD) FVIII (one of the therapeutic FVIII variants used in replacement therapy for haemophilia A) as tolerogenic antigens. This evidence concerns the gene F8 and hemophilia A.